Carfilzomib and Belatacept for Desensitization

(

ADAPT

)

ITN Protocol #:

ITN089ST

Branded Name:

ADAPT

ClinicalTrials.Gov ID:

NCT05017545

Treatment Protocol #:

Therapeutic Area:

Transplantation

Current Status:

Enrollment

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Measuring the Impact of Carfilzomib and Belatacept on Allogeneic Desensitization in Prospective Kidney Transplant Recipients

Clinical Operations Manager

ITN Biologist

ITN Clinical Trial Physician

Rho Data Manager

Rho Scientist

Study Personnel:

Protocol Chair

Stuart Knechtle stuart.knechtle@duke.edu

Work:

919-613-9687

Protocol Chair

Michele DesMarais mdesmarais@immunetolerance.org

Work:

415-420-4250

Protocol Chair

Juliete Francisco Da Silva, PhD jsilva@immunetolerance.org

Work:

205-960-1065

Protocol Chair

Sindhu Chandran, MD schandran@immunetolerance.org

Work:

415-610-4284

Protocol Chair

Brian Goekerman Brian_Goeckerman@rhoworld.com

Work:

919.595.6874

Protocol Chair

Theresa Scocca Theresa_Scocca@rhoworld.com

Work:

919-595-6312

Admin Links

Shortcuts

ITN Documents

Links